Trials / Completed
CompletedNCT03782467
Phase 1 Study in Patients With Advanced and/or Refractory Solid Malignancies to Evaluate the Safety of ATOR-1015
A First-in-human, Multicenter, Open-label, Phase 1 Study in Patients With Advanced and/or Refractory Solid Malignancies to Evaluate the Safety of Intravenously Administered ATOR-1015
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 33 (actual)
- Sponsor
- Alligator Bioscience AB · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The aim of the study is to investigate the safety and tolerability of ATOR-1015 when administered as repeated intravenous infusions to patients with advanced and/or refractory solid malignancies.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | ATOR-1015 | Bispecific human monoclonal antibody targeting cytotoxic T-lymphocyte associated protein 4 (CTLA-4) and OX40 (also known as CD134) |
Timeline
- Start date
- 2019-01-30
- Primary completion
- 2021-03-03
- Completion
- 2021-03-03
- First posted
- 2018-12-20
- Last updated
- 2022-08-18
Locations
5 sites across 2 countries: Denmark, Sweden
Source: ClinicalTrials.gov record NCT03782467. Inclusion in this directory is not an endorsement.